Treating body dysmorphic disorder using medication

Psychiatric Annals

Volumn 34, Issue 12, 2004, Pages 945-953

  Phillips, Katharine A ^a,b  

^a BROWN UNIVERSITY   (United States)

^b BUTLER HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; LITHIUM; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PIMOZIDE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

BEHAVIOR; BODY DYSMORPHIC DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DELUSION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SCREENING; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL DISEASE; HUMAN; LONG TERM CARE; MEDICAL RESEARCH; MENTAL PATIENT; METHODOLOGY; MONOTHERAPY; PATIENT CARE; PSYCHOPHARMACOLOGY; RATING SCALE; RELAPSE; REMISSION; RETROSPECTIVE STUDY; REVIEW; SEIZURE; SUICIDAL BEHAVIOR; SYMPTOM; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 12744268266     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-20041201-18     Document Type: Review

References (28)

1. Hollander E, Liebowitz MR, Winchel R, Klumker A, Klein DF. Treatment of body-dysmorphic disorder with serotonin reuptake blockers. Am J Psychiatry. 1989;146(6): 768-770
2. Phillips KA. Body dysmorphic disorder: the distress of imagined ugliness. Am J Psychiatry. 1991;148(9):1138-1149.
3. Phillips KA. The Broken Mirror: Understanding and Treating Body Dysmorphic Disorder. New York, NY: Oxford University Press. In press.
4. Phillips KA. Pharmacologic treatment of body dysmorphic disorder: review of the evidence and a recommended treatment approach. CNS Spectrums. 2002;7(6):453-460.
5. Phillips KA. Body dysmorphic disorder. In: Phillips KA, ed. Somatoform and Factitious Disorders. Washington, DC: American Psychiatric Publishing; 2001. Oldham JM, Riba MB, eds. Review of Psychiatry Series; vol. 20, no. 3.
6. Phillips KA. Body dysmorphic disorder. In: Phillips KA, ed. Somatoform and Factitious Disorders. Washington, DC: American Psychiatric Publishing; 2001. Oldham JM, Riba MB, eds. Review of Psychiatry Series; vol. 20, no. 3.
7. Phillips KA, Pagano ME, Fay C, Menard W. Pharmacotherapy received by individuals with body dysmorphic disorder. In: Abstracts, National Institute of Mental Health NCDEU 44th Annual Meeting. Phoenix, AZ; 2004:229.
8. Brady KT, Austin L, Lydiard RB. Body dysmorphic disorder: the relationship to obsessive-compulsive disorder. J Nerv Ment Dis. 1990;178(8):538-540.
9. Hollander E, Allen A, Kwon J, et al. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry. 1999;56(11):1033-1039.
10. Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry. 2002;59(4):381-388.
11. Phillips KA, Rasmussen SA. Change in psychosocial functioning and quality of life in body dysmorphic disorder with fluoxetine versus placebo. Psychosomatics. 2004;45(5): 438-444.
12. Phillips KA, Dwight MM, McElroy SL. Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry. 1998;59(4):165-171.
13. Perugi G, Giannotti D, Di Vaio S, et al. Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). Int Clin Psychopharmacol. 1996;11(4):247-254.
14. Phillips KA, Najjar F. An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry. 2003;64(6):715-720.
15. Phillips KA, Albertini RS, Siniscalchi JM, Khan A, Robinson M. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. J Clin Psychiatry. 2001;62(9):721-727.
16. Allen A, Hadley SJ, Kaplan A, et al. An open-label trial of venlafaxine in body dysmorphic disorder. Presented at: 6th International Obsessive Compulsive Disorder Conference Abstracts; November 13-15, 2003; Lanzarote, Spain.
17. Phillips KA, McElroy SL, Dwight MM, Eisen JL, Rasmussen SA. Delusionality and response to open-label fluvoxamine in body dysmorphic disorder. J Clin Psychiatry. 2001;62(2):87-91.
18. Phillips KA, McElroy SL, Keck PE Jr, Hudson JI, Pope HG Jr. A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases. Psychopharmacol Bull. 1994;30(2):179-186.
19. Hollander E, Cohen L, Simeon D, et al. Fluvoxamine treatment of body dysmorphic disorder. J Clin Psychopharmacol. 1994;14(1):75-77.
20. Phillips KA, McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI. Body dysmorphic disorder: 30 cases of imagined ugliness. Am J Psychiatry. 1993;150(2):302-308.
21. Phillips KA. Pharmacologic treatment of body dysmorphic disorder. Psychopharmacol Bull. 1996;32(4):597-605.
22. Grant JE. Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report. J Clin Psychiatry. 2001; 62(4):297-298.
23. Albertini RS, Phillips KA. Thirty-three cases of body dysmorphic disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1999;38(4):453-459.
24. Jain S, Grant JE, Menard W, et al. A chart-review study of SRI continuation treatment versus discontinuation in body dysmorphic disorder. In: Abstracts, National Institute of Mental Health NCDEU 44th Annual Meeting. Phoenix, AZ; 2004:231.
25. Phillips KA. A placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry. In press.
26. Phillips KA. An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder. Psychopharmacol Bull. 1996;32(1):175-180.
27. Carroll BJ, Yendrek R, Degroot C, Fanin H. Response of major depression with psychosis and body dysmorphic disorder to ECT. Am J Psychiatry. 1994;151(2):288-289.
28. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Publishing; 1994.